ArticleAsian Pacific journal of cancer prevention : APJCP2025
CD 14 Expression in Urothelial Carcinoma of The Urinary Bladder (Histopathological and Immunohistochemical Study).
Article in Asian Pacific journal of cancer prevention : APJCP, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEgypt has a significantly higher prevalence of cancer bladder than the rest of the world. CD-14 antigen is involved in Toll-like receptor-mediated signaling pathways in inflammatory tumor microenvironment which promote tumor development and proliferation. There have been few studies on CD14 antigen effect on urothelial carcinoma of the urinary bladder. This study aimed to evaluate the role of CD14 in prognosis of uurothelial carcinoma of the urinary bladder and its association with the tumor progression. MATERIAL AND
methodsThis retrospective cross-sectional study included fifty-one cases of urothelial carcinoma obtained either by cystoscopic biopsies or radical cystectomies. They were immunohistochemically stained using anti- CD14 antibody. Statistical correlations between CD14 expression and available clinicopathological data were done.
resultsPositive immunoexpression of CD14 was noted in 84.3% of all cases, showing scores 1, 2 & 3 in 9.8%, 29.4%, and 45.1% of cases, respectively. While negative immunoexpression was noted in 15.7% of cases and was scored as 0. A statistically significant correlation was noticed between CD14 immunohistochemical expression and each of the tumor grade, pathological tumor stage, status of muscle invasion, and pathological lymph node stage (P value=0.045, 0.030, 0.001, and 0.008 respectively). However, no statistically significant correlation was noted between CD14 immunohistochemical expression and each of the two-year survival rates in radical cystectomy cases and the mortality rate after exclusion of the postoperative complications (P value = 0.114 & 0.156 respectively).
conclusionThe intensity of CD14 expression was weak and even lost in high-grade and late-stage urothelial bladder carcinoma cases, while low-grade urothelial carcinoma cases showed CD14 overexpression. Accordingly, the significance of therapeutic approaches targeting CD14 in high-grade and late-stage urothelial bladder carcinoma shall be questionable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.